Advertisement
Document › Details
Illumina, Inc.. (6/28/19). "Press Release: Illumina Files Patent Infringement Suits Related to BGI in Switzerland, Turkey and the US". San Diego, CA.
Region | Switzerland | |
Organisation | Illumina Inc. (Nasdaq: ILMN) | |
Group | Illumina (Group) | |
Product | BGISeq-500 sequencing system | |
Product 2 | reagents (bio/biochemical) | |
Person | Dadswell, Charles (Illumina 201604 SVP + General Counsel) | |
Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed three additional patent infringement suits relating to BGI’s sequencing products, including the BGISeq-500, MGISeq-2000, and related chemistry reagents.
The first complaint was filed against Complete Genomics, Inc. and other BGI entities in the United States District Court for the Northern District of California alleging infringement of U.S. Patent Nos. 7,566,537 and 9,410,200. The second complaint was filed against Latvia MGI Tech SIA in the Federal Patent Court in Switzerland alleging infringement of EP 1 530 578 B1 and EP 1 828 412 B1. A third complaint was filed against BGI’s distributor, Genoks Genetik Hastaliklar Tani Merkezi, in the Istanbul Civil Court for Intellectual and Industrial Rights in Turkey alleging infringement of EP 3 002 289 B1.
The patents cover Illumina’s proprietary sequencing-by-synthesis chemistry. These lawsuits follow related patent suits filed by Illumina against BGI in Germany and Denmark.
“We believe BGI’s infringement is pervasive. Their continued unauthorized infringement requires that we enforce our intellectual property and protect the substantial investments that have been made in our sequencing-by-synthesis chemistry,” said Charles Dadswell, Senior Vice President and General Counsel for Illumina.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
Illumina, Inc.
Investors:
Jacquie Ross, CFA
+1-858-255-5243
IR@illumina.com
or
Media:
Eric Endicott
858-882-6822
pr@illumina.com
or
Media – Europe:
Karen Birmingham
+44(0) 7500105665
kbirmingham@illumina.com
Record changed: 2023-06-05 |
Advertisement
More documents for Illumina (Group)
- [1] Broken String Biosciences Ltd.. (9/18/23). "Press Release: Broken String Biosciences Closes $15M Series A Funding Round". Cambridge....
- [2] Illumina, Inc.. (7/18/23). "Press Release: The Alliance for Genomic Discovery Announces Founding Biopharma Members – AbbVie, Amgen, AstraZeneca, Bayer, and Merck". San Diego, CA....
- [3] Illumina, Inc.. (7/14/20). "Press Release: Illumina Acquires Enancio’s Compression Software. Reduces Genomic Data Storage and Transfer Costs Associated with the Data Deluge"....
- [4] Roche. (1/13/20). "Press Release: Roche and Illumina Partner to Broaden Patient Access to Genomic Testing". Basel....
- [5] Illumina, Inc.. (10/7/19). "Press Release: Illumina and Qiagen Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests". San Diego, CA & Hilden & Germantown, MD....
- [6] Qiagen N.V.. (10/7/19). "Press Release: Qiagen Reports Preliminary Q3 2019 Results and Announces Measures to Prioritize Resource Allocation". Venlo....
- [7] Thrive Earlier Detection Corporation. (8/1/19). "Press Release: Thrive Earlier Detection Announces Appointment of David J. Daly as Chief Executive Officer". Cambridge, MA....
- [8] Illumina, Inc.. (6/17/19). "Press Release: Illumina Wins Infringement Suit Against Ariosa Diagnostics, Inc.". San Diego, CA....
- [9] Illumina, Inc.. (3/29/19). "Press Release: Illumina Files Patent Infringement Suit against BGI in Germany". San Diego, CA....
- [10] BlueBee. (6/12/18). "Press Release: Lexogen and BlueBee Collaborate to Streamline QuantSeq-UMI Sequencing Data Analysis Pipeline". Vienna & Rijswijk....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top